InsidersTradesSigma
Total declarations
Company
▲ Purchases (8 ops.)
▼ Sales (0 ops.)
Insider track record
Board DirectorDisclosed buys
8
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Browse the complete record of transactions filed by KOTLER KEVIN, Director. Officer active across 1 company, notably Biodelivery Sciences International INC. In total, 14 filings have been logged. Split: 8 buys · 0 sell. Total volume traded: €3.4m. History available since 11 May 2021. The latest transaction was filed on 22 March 2022 (J). Regulator: SEC (Form 4). The full history is openly available.
Declarations14 total
7,588,395 shares0Common StockSEC:0001103021-22-000069:0
2,422,222 shares@ US$1.8052.7% of flowCommon StockSEC:0001103021-22-000047:0
7,684 shares0Common StockSEC:0001103021-22-000022:0
7,684 shares0Common StockSEC:0001103021-22-000022
100,000 shares@ US$3.063.7% of flowCommon StockSEC:0001103021-21-000120:0
Ideal exit: 16 Aug 2022 (T+270)
100,000 shares@ US$3.0615.7% of flowCommon StockSEC:0001103021-21-000120
Ideal exit: 16 Aug 2022 (T+270)
100,000 shares@ US$3.203.9% of flowCommon StockSEC:0001103021-21-000114:0
Ideal exit: 9 Aug 2022 (T+270)
100,000 shares@ US$3.2016.3% of flowCommon StockSEC:0001103021-21-000114
Ideal exit: 9 Aug 2022 (T+270)
257,800 shares@ US$3.4710.7% of flowCommon StockSEC:0001103021-21-000110:0
Ideal exit: 2 Aug 2022 (T+270)
257,800 shares@ US$3.4745.2% of flowCommon StockSEC:0001103021-21-000110
Ideal exit: 2 Aug 2022 (T+270)
30,000 shares0Common StockSEC:0001103021-21-000072
30,000 shares0Common StockSEC:0001103021-21-000072:0
150,000 shares@ US$3.165.4% of flowCommon StockSEC:0001103021-21-000046
Ideal exit: 5 Feb 2022 (T+270)
150,000 shares@ US$3.165.4% of flowCommon StockSEC:0001103021-21-000046:0
Ideal exit: 5 Feb 2022 (T+270)
14 of 14 declarations
About KOTLER KEVIN
Kevin Kotler is a Board Member at BioDelivery Sciences International Inc. With expertise in the pharmaceutical field, he contributes to the governance and strategy of the company. His role on the board is essential for guiding product development initiatives and ensuring regulatory compliance.
